Orlistat for overweight subjects with nonalcoholic steatohepatitis. by Dowman, J, Stocken, D, Tomlinson, J, Newsome, P, Newsome, P

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. by Dowman, J, Tomlinson, J, Newsome, P

Pathogenesis of non-alcoholic fatty liver disease. by Dowman, J, Tomlinson, J, Newsome, P

The diagnosis of non-alcoholic fatty liver disease: authors' reply by Dowman, J, Tomlinson, J, Newsome, P

Current therapeutic strategies in non-alcoholic fatty liver disease. by Dowman, J, Armstrong, M, Tomlinson, J, Newsome, P

High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program by Armstrong, M, Falahati, A, Braun, O, Schmidt, W, Gough, S, Newsome, P

High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program by Armstrong, M, Falahati, A, Elbrond, B, Schmidt, W, Gough, S, Newsome, P

EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL by Armstrong, M, Falahati, A, Houlihan, D, Elbrond, B, Schmidt, W, Gough, S, Newsome, P

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. by Armstrong, M, Houlihan, D, Rowe, I, Clausen, W, Elbrønd, B, Gough, S, Tomlinson, J, Newsome, P

Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme by Armstrong, M, Houlihan, D, Rowe, I, Clausen, W, Elbrond, B, Gough, S, Tomlinson, J, Newsome, P

5-ALPHA-REDUCTASE-1 KNOCKOUT PROTECTS AGAINST HEPATOCARCINOGENESIS IN A MURINE MODEL OF NASH by Dowman, J, Hopkins, L, Armstrong, M, Gathercole, L, Lalor, P, Hubscher, S, Tomlinson, J, Newsome, P

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program by Armstrong, M, Houlihan, D, Rowe, I, Clausen, W, Elbrønd, B, Gough, S, Tomlinson, J, Newsome, P

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. by Armstrong, M, Hazlehurst, J, Hull, D, Guo, K, Borrows, S, Yu, J, Gough, S, Newsome, P, Tomlinson, J

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis by Armstrong, M, Hazlehurst, J, Hull, D, Guo, K, Borrows, S, Yu, J, Gough, S, Newsome, P, Tomlinson, J

Subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis by Armstrong, M, Hazlehurst, J, Hull, D, Borrows, S, Guo, K, Yu, J, Barton, D, Gaunt, P, Gough, S, Tomlinson, J, Newsome, P

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial by Armstrong, M, Barton, D, Gaunt, P, Hull, D, Guo, K, Stocken, D, Gough, S, Tomlinson, J, Brown, R, Hübscher, S, Newsome, P

Cortisol Metabolism and Hepatic Expression of 11 beta-Hydroxysteroid Dehydrogenase Type 1 in Patients with Non Alcoholic Fatty Liver Disease. by Ahmed, A, Brady, T, Brown, C, Guest, P, Wagenmakers, A, Newsome, P, Hubscher, S, Elias, E, Adams, D, Tomlinson, J, Stewart, P

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. by Armstrong, M, Hull, D, Guo, K, Barton, D, Hazlehurst, J, Gathercole, L, Nasiri, M, Yu, J, Gough, S, Newsome, P, Tomlinson, J

Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. by Dowman, J, Hopkins, L, Reynolds, G, Nikolaou, N, Armstrong, M, Shaw, J, Houlihan, D, Lalor, P, Tomlinson, J, Hübscher, S, Newsome, P

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II r... by Armstrong, M, Hull, D, Guo, K, Barton, D, Hazlehurst, J, Nasiri, M, Gathercole, L, Yu, J, Gaunt, P, Gough, S, Tomlinson, J, Newsome, P